

Evidence-based Guideline for Therapeutic Drug Monitoring from the Division of Therapeutic Drug Monitoring, Chinese P

Clinical Infectious Diseases

71, S363-S371

DOI: [10.1093/cid/ciaa1536](https://doi.org/10.1093/cid/ciaa1536)

Citation Report

#	ARTICLE	IF	CITATIONS
1	A case of newly diagnosed immune thrombocytopenia in the COVID-19 era. <i>Internal and Emergency Medicine</i> , 2021, 16, 2221-2225.	1.0	2
2	Mild Cytokine Elevation, Moderate CD4+T Cell Response and Abundant Antibody Production in Children with COVID-19. <i>Virologica Sinica</i> , 2020, 35, 734-743.	1.2	44
3	Patients with Prolonged Positivity of SARS-CoV-2 RNA Benefit from Convalescent Plasma Therapy: A Retrospective Study. <i>Virologica Sinica</i> , 2020, 35, 768-775.	1.2	10
4	Preoperative SARS-CoV-2 screening: Can it really rule out COVID-19?. <i>Canadian Journal of Anaesthesia</i> , 2020, 67, 1321-1326.	0.7	19
5	Coronavirus disease 2019 (COVID-19): update for anesthesiologists and intensivists March 2020. <i>Der Anaesthesist</i> , 2021, 70, 1-10.	0.5	83
6	Contribution of anosmia and dysgeusia for diagnostic of COVID-19 in outpatients. <i>Infection</i> , 2021, 49, 361-365.	2.3	64
7	Tracheostomy care and decannulation during the COVID-19 pandemic. A multidisciplinary clinical practice guideline. <i>European Archives of Oto-Rhino-Laryngology</i> , 2021, 278, 313-321.	0.8	28
8	COVID-19-associated coagulopathy and disseminated intravascular coagulation. <i>International Journal of Hematology</i> , 2021, 113, 45-57.	0.7	271
9	Diagnosis of COVID-19 using multiple antibody assays in two cases with negative PCR results from nasopharyngeal swabs. <i>Infection</i> , 2021, 49, 171-175.	2.3	11
10	Hydroxychloroquine versus lopinavir/ritonavir in severe COVID-19 patients. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 284-291.	1.0	24
11	Learning from the past: development of safe and effective COVID-19 vaccines. <i>Nature Reviews Microbiology</i> , 2021, 19, 211-219.	13.6	126
12	A highly specific and sensitive serological assay detects SARS-CoV-2 antibody levels in COVID-19 patients that correlate with neutralization. <i>Infection</i> , 2021, 49, 75-82.	2.3	118
13	Comparison of four commercial SARS-CoV-2 IgG immuno-assays in RT-PCR negative patients with suspect CT findings. <i>Infection</i> , 2021, 49, 145-148.	2.3	2
14	HIV Care Experiences During the COVID-19 Pandemic: Mixed-Methods Telephone Interviews with Clinic-Enrolled HIV-Infected Adults in Uganda. <i>AIDS and Behavior</i> , 2021, 25, 28-39.	1.4	61
15	Risk factors for Covid-19 severity and fatality: a structured literature review. <i>Infection</i> , 2021, 49, 15-28.	2.3	351
16	Serological assays and host antibody detection in coronavirus-related disease diagnosis. <i>Archives of Virology</i> , 2021, 166, 715-731.	0.9	15
17	COVID-19: advance in laboratory diagnostic strategy and technology. <i>Molecular and Cellular Biochemistry</i> , 2021, 476, 1421-1438.	1.4	8
18	Clinical characteristics of COVID-19 infection in a dialysis center during a nosocomial outbreak. <i>Clinical and Experimental Nephrology</i> , 2021, 25, 652-659.	0.7	9

#	ARTICLE	IF	CITATIONS
19	Clinical correlates of anti-SARS-CoV-2 antibody profiles in Spanish COVID-19 patients from a high incidence region. <i>Scientific Reports</i> , 2021, 11, 4363.	1.6	9
20	Potential intestinal infection and faecal-oral transmission of SARS-CoV-2. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 269-283.	8.2	223
21	Symptoms and syndromes associated with SARS-CoV-2 infection and severity in pregnant women from two community cohorts. <i>Scientific Reports</i> , 2021, 11, 6928.	1.6	22
22	A predictive score at admission for respiratory failure among hospitalized patients with confirmed 2019 Coronavirus Disease: a simple tool for a complex problem. <i>Internal and Emergency Medicine</i> , 2021, , 1.	1.0	7
23	A systematic review of pregnant women with COVID-19 and their neonates. <i>Archives of Gynecology and Obstetrics</i> , 2021, 304, 5-38.	0.8	85
24	Transmission of SARS-CoV-2 before and after symptom onset: impact of nonpharmaceutical interventions in China. <i>European Journal of Epidemiology</i> , 2021, 36, 429-439.	2.5	8
25	Neuropathophysiology of coronavirus disease 2019: neuroinflammation and blood brain barrier disruption are critical pathophysiological processes that contribute to the clinical symptoms of SARS-CoV-2 infection. <i>Inflammopharmacology</i> , 2021, 29, 939-963.	1.9	42
26	Characteristic of IgA and IgG antibody response to SARS-CoV-2 infection in an Italian referral COVID-19 Hospital. <i>Internal and Emergency Medicine</i> , 2022, 17, 53-64.	1.0	7
27	SARS-COV-2 Infection and Specific Antibody Detection on Health Care Workers from a Military Hospital in Madrid, Spain. <i>Current Microbiology</i> , 2021, 78, 2910-2915.	1.0	1
28	Health-related quality of life issues, including symptoms, in patients with active COVID-19 or post COVID-19; a systematic literature review. <i>Quality of Life Research</i> , 2021, 30, 3367-3381.	1.5	53
29	Treatment of Intracranial Infection Caused by Methicillin-Resistant <i>Staphylococcus epidermidis</i> with Linezolid Following Poor Outcome of Vancomycin Therapy: A Case Report and Literature Review. <i>Infection and Drug Resistance</i> , 2021, Volume 14, 2533-2542.	1.1	3
30	Profiles of SARS-CoV-2 RNA and Antibodies in Inpatients with COVID-19 not Related with Clinical Manifestation: A Single Centre Study. <i>Virologica Sinica</i> , 2021, 36, 1088-1092.	1.2	0
31	The negative impact of obesity on the occurrence and prognosis of the 2019 novel coronavirus (COVID-19) disease: a systematic review and meta-analysis. <i>Eating and Weight Disorders</i> , 2022, 27, 893-911.	1.2	28
32	Host factors facilitating SARS-CoV-2 virus infection and replication in the lungs. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 5953-5976.	2.4	19
33	Prevalence of SARS-CoV-2 RNA on inanimate surfaces: a systematic review and meta-analysis. <i>European Journal of Epidemiology</i> , 2021, 36, 685-707.	2.5	8
34	From influenza to SARS-CoV-2: etiological evaluation of acute benign childhood myositis. <i>Acta Neurologica Belgica</i> , 2021, , 1.	0.5	6
35	Relationship between serum osteopontin levels and the severity of COVID-19 infection. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 298-302.	1.0	16
36	Population Pharmacokinetic Modeling and Dose Optimization of Vancomycin in Chinese Patients with Augmented Renal Clearance. <i>Antibiotics</i> , 2021, 10, 1238.	1.5	6

#	ARTICLE	IF	CITATIONS
37	The relationship between vancomycin AUC/MIC and trough concentration, age, dose, renal function in Chinese critically ill pediatric patients. <i>Pharmacology Research and Perspectives</i> , 2021, 9, e00885.	1.1	8
38	Medication therapy of high-dose methotrexate: An evidence-based practice guideline of the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 2456-2472.	1.1	9
39	Dose Optimization of Vancomycin for Critically Ill Patients Undergoing CVWH: A Prospective Population PK/PD Analysis. <i>Antibiotics</i> , 2021, 10, 1392.	1.5	7
40	Degradation of vancomycin in external quality assessment samples is a factor to underestimate its concentration. <i>Bioanalysis</i> , 2021, 13, 1743-1750.	0.6	0
41	Household transmission of SARS-CoV-2 infection in the Paris/Ile-de-France area. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2022, 41, 445-454.	1.3	5
42	SARS-CoV2 infection in symptomatic patients: interest of serological tests and predictors of mortality: experience of DR Congo. <i>BMC Infectious Diseases</i> , 2022, 22, 21.	1.3	3
43	Target serum concentration of vancomycin may be reached earlier with a loading dose. <i>Chinese Medical Journal</i> , 2022, 135, 317-323.	0.9	1
44	Comparison of Vancomycin Clearance Between Augmented Renal Clearance and Normal Renal Function in Critically Ill Infants: A Population Pharmacokinetics Study. <i>Journal of Clinical Pharmacology</i> , 2022, 62, 863-872.	1.0	2
45	Optimal strategies to screen health care workers for COVID-19 in the US: a cost-effectiveness analysis. <i>Cost Effectiveness and Resource Allocation</i> , 2022, 20, 2.	0.6	4
46	The characteristics of overseas imported COVID-19 cases and the effectiveness of screening strategies in Beijing, China. <i>BMC Infectious Diseases</i> , 2022, 22, 59.	1.3	2
47	Optimal Practice for Vancomycin Therapeutic Drug Monitoring: Position Statement From the Anti-infectives Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. <i>Therapeutic Drug Monitoring</i> , 2022, 44, 121-132.	1.0	18
48	Quantification of Antibiotics in Patient Samples: State of the Art in Standardization and Proficiency Testing. <i>Therapeutic Drug Monitoring</i> , 2022, 44, 230-240.	1.0	2
49	Clinical Practice Guidelines for Therapeutic Drug Monitoring of Vancomycin in the Framework of Model-Informed Precision Dosing: A Consensus Review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. <i>Pharmaceutics</i> , 2022, 14, 489.	2.0	43
50	Therapeutic drug monitoring of vancomycin in neurosurgery patients, from trough concentration to area under the curve: a retrospective single center cohort study in a tertiary hospital. <i>Journal of International Medical Research</i> , 2022, 50, 030006052210832.	0.4	3
51	Impact of pharmacist intervention in reducing vancomycin-associated acute kidney injury: A systematic review and meta-analysis. <i>British Journal of Clinical Pharmacology</i> , 2022, , .	1.1	3
52	Pharmacokinetics and pharmacodynamics of peptide antibiotics. <i>Advanced Drug Delivery Reviews</i> , 2022, 183, 114171.	6.6	13
53	Treatments, resource utilization, and outcomes of COVID-19 patients presenting to emergency departments across pandemic waves: an observational study by the Canadian COVID-19 Emergency Department Rapid Response Network (CCEDRRN). <i>Canadian Journal of Emergency Medicine</i> , 2022, 24, 397-407.	0.5	17
54	Case Report: Monitoring Vancomycin Concentrations and Pharmacokinetic Parameters in Continuous Veno-Venous Hemofiltration Patients to Guide Individualized Dosage Regimens: A Case Analysis. <i>Frontiers in Pharmacology</i> , 2021, 12, 763575.	1.6	1

#	ARTICLE	IF	CITATIONS
56	Household quarantine of second degree contacts is an effective non-pharmaceutical intervention to prevent tertiary cases in the current SARS-CoV pandemic. <i>BMC Infectious Diseases</i> , 2021, 21, 1262.	1.3	1
57	Two Innovative Approaches to Optimize Vancomycin Dosing Using Estimated AUC after First Dose: Validation Using Data Generated from Population PK Model Coupled with Monte-Carlo Simulation and Comparison with the First-Order PK Equation Approach. <i>Pharmaceutics</i> , 2022, 14, 1004.	2.0	2
58	Severe Thrombocytopenia Caused by Vancomycin in the Intensive Care Unit: A Case Report. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	1
59	Association between Augmented Renal Clearance and Inadequate Vancomycin Pharmacokinetic/Pharmacodynamic Targets in Chinese Adult Patients: A Prospective Observational Study. <i>Antibiotics</i> , 2022, 11, 837.	1.5	5
60	Vancomycin dosing in an obese patient with acute renal failure: A case report and review of literature. <i>World Journal of Clinical Cases</i> , 2022, 10, 6218-6226.	0.3	1
61	Antimicrobial safety considerations in critically ill patients: part I: focused on acute kidney injury. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 551-561.	1.3	0
62	Optimization of the vancomycin administration regimen by clinical pharmacists based on a population pharmacokinetics model: a prospective interventional study. <i>Journal of Chemotherapy</i> , 0, , 1-13.	0.7	0
63	Clinical Application Value of Pharmacokinetic Parameters of Vancomycin in Children Treated in the Pediatric Intensive Care Unit. <i>Frontiers in Pediatrics</i> , 0, 10, .	0.9	1
64	Assessment of an institutional guideline for vancomycin dosing and identification of predictive factors associated with dose and drug trough levels. <i>Journal of Infection</i> , 2022, 85, 382-389.	1.7	1
65	Review and evaluation of vancomycin dosing guidelines for obese individuals. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2022, 18, 323-335.	1.5	2
66	Relationship between Vancomycin Trough Serum Concentrations and Clinical Outcomes in Children: a Systematic Review and Meta-Analysis. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, .	1.4	2
67	Establishment of relapse risk model and multivariate logistic regression analysis on risk factors of relapse in children with primary nephrotic syndrome. <i>Medicine (United States)</i> , 2022, 101, e29866.	0.4	0
68	Continuous infusion versus intermittent infusion of vancomycin in critically ill patients undergoing continuous venovenous hemofiltration: a prospective interventional study. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	2
69	Pharmacokinetic assessment of vancomycin in critically ill patients and nephrotoxicity prediction using individualized pharmacokinetic parameters. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	0
70	Sequence Type 5 (ST5) as a Possible Predictor of Bacterial Persistence in Adult Patients with Methicillin-Resistant <i>Staphylococcus aureus</i> Pneumonia Treated with Vancomycin. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	2
71	Therapeutic drug monitoring practices of anti-infectives: An Asia-wide cross-sectional survey. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	2
72	Therapeutic drug monitoring (TDM) as intervention: A cross-sectional analysis of characteristics of 173 registered clinical trials. <i>Contemporary Clinical Trials Communications</i> , 2022, 30, 101014.	0.5	3
74	Analysis of a machine learning-based risk stratification scheme for acute kidney injury in vancomycin. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	0

#	ARTICLE	IF	CITATIONS
75	Therapeutic drug monitoring of free vancomycin concentration in practice: A new analytical technique based on the HFCFâ€“UF sample separation method. <i>Biomedical Chromatography</i> , 0, , .	0.8	0
76	evaluaci3n de desempeÃ±o del servicio de dosificaci3n de precisi3n para vancomicina en un hospital pedi3trico de nivel terciario. <i>Revista De La Facultad De Ciencias Medicas De Cordoba</i> , 2022, 79, 341-346.	0.1	0
77	Population Pharmacokinetics and Dosage Optimization of Vancomycin in Pediatric Patients with Skin and Soft Tissue Infections, Bone, and Joint Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 0, , .	1.4	0
78	Adapted Evidence-Based Clinical Practice Guidelines for Diagnosis and Treatment of Epilepsies in Children: A Tertiary Children's Hospital Update. <i>Pediatric Neurology</i> , 2023, 141, 87-92.	1.0	0
80	Should the trough concentration of vancomycin be abandoned in therapeutic drug monitoring? A multicentre, retrospective study of critically ill patients without any form of dialysis. <i>International Journal of Antimicrobial Agents</i> , 2023, 61, 106812.	1.1	1
81	Determination of vancomycin exposure target and individualized dosing recommendations for critically ill patients undergoing continuous renal replacement therapy. <i>Pharmacotherapy</i> , 2023, 43, 180-188.	1.2	1
82	Therapeutic Drug Monitoring of Vancomycin Concentrations for the Management of Bone and Joint Infections: An Urgent Need. <i>Tropical Medicine and Infectious Disease</i> , 2023, 8, 113.	0.9	0
83	Optimal Use and Need for Therapeutic Drug Monitoring of Teicoplanin in Children: A Systematic Review. <i>Journal of Korean Medical Science</i> , 2023, 38, .	1.1	0
84	A national survey of individualized pharmaceutical care practice in Chinese hospitals in 2019. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	1
85	Optimization of Voriconazole Dosing Regimens Against <i>Aspergillus</i> Species and <i>Candida</i> Species in Pediatric Patients After Hematopoietic Cell Transplantation: A Theoretical Study Based on Pharmacokinetic/Pharmacodynamic Analysis. <i>Journal of Clinical Pharmacology</i> , 2023, 63, 993-1001.	1.0	0